FDA Approves Aduhelm

FDA Grants Accelerated Approval for Aduhelm (aducanumab-avwa) for the Treatment of Alzheimer’s Disease CAMBRIDGE, Mass. and TOKYO, June 07, 2021 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that

FDA Approves Pylarify

FDA Approves Pylarify (piflufolastat F 18) PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer May 27, 2021 — FDA has approved Pylarify (piflufolastat F 18) – a drug for positron emission tomography (PET) imaging of

FDA Approves Fotivda

FDA Approves Fotivda (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma BOSTON–(BUSINESS WIRE) March 10, 2021 — AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and

Bactroban Cream

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. BACTROBAN®CREAM Mupirocin Consumer Medicine Information What is in this leaflet? Please read this leaflet carefully before you start using BACTROBAN cream, or

Puregon

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. PUREGON® CMI A141217v1 follitropin beta[rch] Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about PUREGON. It

APOHEALTH Dry Tickly Cough Relief FORTE

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. APOHEALTH Dry Tickly Cough Relief FORTE Oral Liquid Contains the active ingredient Pholcodine Consumer Medicine Information What is in this leaflet Read

Ventolin Sugar Free Syrup

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. VENTOLIN® SUGAR FREE SYRUP Salbutamol sulphate Consumer Medicine Information What is in this leaflet? Please read this leaflet carefully before you take

Bactroban Nasal Ointment

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. BACTROBAN® NASAL OINTMENT NASAL OINTMENT Mupirocin Consumer Medicine Information What is in this leaflet? Please read this leaflet carefully before you use

APO-Prochlorperazine Nausea Relief

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. APO-PROCHLORPERAZINE NAUSEA RELIEF TABLETS Contains the active ingredient, prochlorperazine (as maleate) Consumer Medicine Information What is in this leaflet Read this leaflet